Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study

Cesare Cuspidi, M. Lorenza Muiesan, Laura Valagussa, Massimo Salvetti, Carlo Di Biagio, Enrico Agabiti-Rosei, Bruno Magnani, Alberto Zanchetti, E. Bartoli, F. Bux, V. Calcaterra, S. Pancaldi, A. Capucci, G. Devenuto, R. De Cesaris, G. Di Biase, G. Di Pasquale, M. Guglielmi, A. Mezzetti, G. PinelliG. Pinna, F. Portaluppi, I. Russo, G. Saba, T. Scarpelli, E. Uslenghi, M. Keck, T. Beyer, K. H. Tepel, H. Schobel, U. Stolzel, B. Metscher, S. Gehlhar, H. Loos, K. Busch, G. Clasen, T. R. Muller, K. Colberg, C. Ulbrich, D. Langguth, V. Mitrovich, V. Regitz-Zagrosek, M. Rittich, J. L. Weber

Research output: Contribution to journalArticle

Abstract

Background: A limited number of studies have evaluated the effect of angiotensin II receptor antagonists (AIIAs) on left ventricular hypertrophy (LVH) in comparison with other antihypertensive drugs, and no large study has compared AIIAs with angiotensin-converting enzyme inhibitors (ACEIs). Methods and results: The CATCH (Candesartan Assessment in the Treatment of Cardiac Hypertrophy) study was a multicenter prospective randomized double-blind trial comparing the effects of candesartan cilexetil (8-16 mg once daily) and enalapril (10-20 mg once daily) with possible addition of hydrochlorothiazide (12.5-25 mg once daily) on echocardiographic left ventricular mass index (LVMI), in 239 hypertensives with LVH (LVMI>120 g/m2 in men and >100 g/m2 in women). Two-dimensionally guided M-mode echocardiograms were carried out at screening (recruiting scan), randomization (baseline scan) and after 24 and 48 weeks of treatment. Baseline and treatment echocardiograms were read at two central labs without knowledge of the scan time sequence. In intention-to-treat (ITT) analyses (196 patients), systolic and diastolic blood pressures (SBP, DBP) were significantly and equally reduced by the two treatments. Candesartan and enalapril reduced LVMI to the same extent, i.e. by 15.0 and 13.1 g/m2 (-10.9 and -8.4%; P

Original languageEnglish
Pages (from-to)2293-2300
Number of pages8
JournalJournal of Hypertension
Volume20
Issue number11
DOIs
Publication statusPublished - Nov 2002

    Fingerprint

Keywords

  • Drugs
  • Echocardiography
  • Hypertension
  • Hypertrophy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Cuspidi, C., Muiesan, M. L., Valagussa, L., Salvetti, M., Di Biagio, C., Agabiti-Rosei, E., Magnani, B., Zanchetti, A., Bartoli, E., Bux, F., Calcaterra, V., Pancaldi, S., Capucci, A., Devenuto, G., De Cesaris, R., Di Biase, G., Di Pasquale, G., Guglielmi, M., Mezzetti, A., ... Weber, J. L. (2002). Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. Journal of Hypertension, 20(11), 2293-2300. https://doi.org/10.1097/00004872-200211000-00030